A study conducted by researchers at the University of Aberdeen (Scotland) has found that pelvic organ prolapse repairs reinforced by non-absorbable synthetic mesh are no more effective than standard native tissue repair.
The results of the study were published recently in the medical journal The Lancet.
The PROSPECT study, a national collaborative research project involving 1348 women, is the largest randomized trial of the use of mesh in transvaginal prolapse surgery.
Researchers determined that the mesh, inserted through the vagina, resulted in a number of complications but did not offer any clear benefits, and concluded that the use of pelvic mesh in such procedures could be considered an “unnecessary risk,” until further research is conducted.
Pelvic mesh made of polypropylene is used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
First introduced to the market in the mid-1990s, the pelvic mesh is implanted transvaginally (through the vagina) and was first approved by the FDA under a 501(k) process based on a similarity to other mesh products already on the market.
As a result, many transvaginal mesh products were approved before they were ever tested on humans.
Millions of women have had transvaginal mesh surgery and many procedures have resulted in severe and sometimes permanent injury.
Pelvic mesh lawsuits allege that the device has a defective design that erodes the surrounding tissue, leads to excessive scar tissue growth, and is difficult to remove if it does not work properly.
In one recent lawsuit, Boston Scientific, the manufacturer of the pelvic mesh product Obtryx, failed in its effort to appeal awards totaling $18.5 million awarded to four different women.
The company was ordered to pay each plaintiff up to $4.25 million in compensatory damages for injuries related to the Obtryx mesh.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.
Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.
Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
Weis Market Inc., a Mid-Atlantic food retailer based in Sunbury, Pennsylvania, has recalled its 48-ounce containers of Weis Quality Brownie Moose Tracks Ice Cream because the product may contain traces of egg, an allergen not declared on the ingredient statement label, according to the FDA.
Marlex Pharmaceuticals, Inc., of New Castle, Delaware, has announced a voluntary, consumer-level recall of one lot of Digoxin Tablets USP, 0125mg, as well as one lot of Digoxin Tablets USP, 0.25mg, because the labels of both products have been mixed up, according to the FDA.